Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt™ PFA System to treat patients battling atrial fibrillation (AFib). Abbott will soon begin ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

NFL players, coaches and staff put their bodies on the line every season. They sacrifice health, time, energy and more for a chance to win a Super Bowl. When that season eventually comes to an end, it ...

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

Jim Harbaugh told reporters Tuesday he had two successful surgeries during the 2025 NFL offseason. One was a hip replacement; the other was a cardiac ablation done after the 61-year-old coach ...

MIT-alumni-founded Thermedical advances novel deep-tissue ablation technology to address critical unmet needs in severe ventricular tachycardia ...

Irregular heartbeats, or arrhythmia, can significantly affect a person’s quality of life and overall health. When medication and lifestyle changes are ineffective, doctors may recommend surgery to ...

Abbott Laboratories (NYSE:ABT) picked up a meaningful win Monday after the FDA approved its Volt Pulsed Field Ablation system for treating atrial fibrillation, a condition that affects millions of ...

Abbott Laboratories is set to roll out its Volt PFA System in the U.S., following federal approval, and continue expanding ...

Cardiac Ablation Market OverviewThe cardiac ablation market is set to grow at an impressive CAGR of approximately 13% over the forecast period, driven by a combination of clinical, technological, and ...